Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ASND
ASND
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ASND News
BridgeBio Pharma Stock Soars on Positive Clinical Trial Results
3d ago
Benzinga
Ascendis Pharma Reports Strong 2025 Financial Results and Growth Outlook
3d ago
Yahoo Finance
Ascendis Pharma Reports Strong FY Earnings, Surpassing Expectations
3d ago
seekingalpha
Ascendis Pharma Reports Strong 2025 Financial Results and Growth Outlook
3d ago
Yahoo Finance
Ascendis Pharma Q4 Earnings Announcement Scheduled
4d ago
seekingalpha
FDA Approves Zycubo for Pediatric Menkes Disease Treatment
Jan 28 2026
NASDAQ.COM
Ascendis Pharma (ASND) Stock Rises 7.5% Amid Takeover Speculation
Jan 22 2026
seekingalpha
Ascendis Pharma Updates 2026 Strategic Roadmap, Projects €683 Million Revenue
Jan 09 2026
Globenewswire
Ascendis Pharma Reports Positive Phase 2 Results for Pediatric Achondroplasia Treatment
Jan 09 2026
NASDAQ.COM
Evaluating Ascendis Pharma's 2025 Valuation Following Significant Gains and DCF Growth Potential
Dec 21 2025
Yahoo Finance
Ascendis Pharma Rises on Acquisition Rumors
Dec 12 2025
SeekingAlpha
March 2026 Options for Ascendis Pharma (ASND) Now Open for Trading
Dec 12 2025
NASDAQ.COM
Eight Stock Selections to Capitalize on a Robust Sector of the Market
Dec 11 2025
MarketWatch
The Biotech Sector Is Stronger Than Investors Realize: Key Stocks to Monitor.
Dec 04 2025
Barron's
Impact of FDA's Delay in Reviewing TransCon CNP at Ascendis Pharma (ASND) on Its Investment Narrative
Nov 29 2025
Yahoo Finance
Ascendis Pharma Faces FDA Setback as TransCon CNP Decision Postponed to 2026
Nov 28 2025
Benzinga
Show More News
